Mannan Pharmaceuticals LLC Establishing R&D Operations In Greenville County
Company Seeking Cures For Muscular Dystrophies And Metastatic Cancers To Create Up To 34 Jobs
COLUMBIA, S.C. – August 20, 2014 - Mannan Pharmaceuticals LLC, an organization dedicated to developing and delivering effective pharmaceutical solutions to various muscular dystrophies (MDs) and metastatic cancers, is establishing research and development (R&D) operations in Greenville County. In locating at the Institute for Translational Oncology Research (ITOR) of Greenville Health System (GHS), Mannan plans to expand its R&D team to create up to 34 new positions over the next several years.
Mannan is the first pharmaceutical company to pioneer the development of compound-based drugs that target a novel pathway to treat various MDs and metastatic cancers. With the World Health Organization reporting an estimated 8.2 million cancer-related deaths in 2012, and forecasts of 19.3 million new cancer cases per year by 2025 due to population growth and aging, the anti-cancer drug market is estimated to approach nearly $200 billion by 2015. At least 50 types of MDs have been identified, impacting over 500,000 patients worldwide. Mannan Pharmaceuticals’ drugs in development are anticipated to target more than half of all MD patients, a drug market estimated at nearly $15 billion.
Mannan Pharmaceuticals LLC is a privately held company and had been considering locations nationwide before deciding to open at ITOR, according to the company. Mannan expects to add up to three more associates in 2014 and then will continue to grow and expand its team over time as investment and developments warrant.
Details on hiring plans and specific position requirements will be announced in late fall.